NXS.AU · Next Science Limited

-

Please sign in to comment on NXS.AU

1 Comment

Admin

4 years, 1 month ago

Next Science Limited is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.

From a valuation standpoint, the stock is 78.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.4.

Next Science Limited's total revenue rose by 39.1% to $2M since the same quarter in the previous year.

Its net income has increased by 32.9% to $-5M since the same quarter in the previous year.

Finally, its free cash flow grew by 14.6% to $-4M since the same quarter in the previous year.

Based on the above factors, Next Science Limited gets an overall score of 5/5.

Sector	Healthcare
Exchange	AU
CurrencyCode	AUD
ISIN	AU0000041329
Industry	Drug Manufacturers - Specialty & Generic

PE Ratio	None
Beta	1.31
Market Cap	28M
Target Price	0.265
Dividend Yield	None

ABOUT

Next Science Limited

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

NXS.AU · Next Science Limited

-

Next Science Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Next Science Limited using a moving average strategy